Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV

by Mazzotta, Valentina , Castilletti, Concetta , De Pascale, Lydia , Cicalini, Stefania , Garbuglia, AnnaRosa , Matusali, Giulia , Bordoni, Veronica , Marani, Alessandra , Antinori, Andrea , Vergori, Alessandra , Meschi, Silvia , Cimini, Eleonora , Puro, Vincenzo , Gallì, Paola , Agrati, Chiara , Vaia, Francesco , Lanini, Simone , Iannazzo, Roberta , Girardi, Enrico , Cozzi Lepri, Alessandro , Mariotti, Davide , Colavita, Francesca , Mastrorosa, Ilaria

in 2019-nCoV Vaccine mRNA-1273 / 631/250/590/2293 / 631/326/596/4130 / 692/308/409 / 692/699/255/1901 / Antibodies, Viral / Antiretroviral therapy / BNT162 Vaccine / CD4 antigen / Cell-mediated immunity / COVID-19 / COVID-19 - prevention & control / COVID-19 Vaccines - immunology / HIV / HIV Infections / Human immunodeficiency virus / Humanities and Social Sciences / Humans / Immune response / Immune response (humoral) / Immune system / Immunity / Immunogenicity / Immunogenicity, Vaccine / Middle Aged / mRNA / mRNA vaccines / multidisciplinary / Public health / SARS-CoV-2 / Science / Science (multidisciplinary) / Severe acute respiratory syndrome coronavirus 2 / Vaccination / Vaccines / Viral diseases / γ-Interferon

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV

2022

Confirm

Do you wish to request the book?

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV

Mazzotta, Valentina,

Castilletti, Concetta,

De Pascale, Lydia,

Cicalini, Stefania,

Garbuglia, AnnaRosa,

Matusali, Giulia,

Bordoni, Veronica,

Marani, Alessandra,

Antinori, Andrea,

Vergori, Alessandra,

Meschi, Silvia,

Cimini, Eleonora,

Puro, Vincenzo,

Gallì, Paola,

Agrati, Chiara,

Vaia, Francesco,

Lanini, Simone,

Iannazzo, Roberta,

Girardi, Enrico,

Cozzi Lepri, Alessandro,

Mariotti, Davide,

Colavita, Francesca,

Mastrorosa, Ilaria

2022

Overview

In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm 3 and/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45 cell/mm 3 (20–122), 93% HIV-RNA < 50 c/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (>2 log 2 difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation. HIV infection may affect the immune response to vaccination. Here the authors show that humoral response in persons living with HIV after the third dose of a SARS-CoV-2 vaccine is strong and higher than that achieved with the second dose, while cell-mediated immunity remains stable.

Share this book

Add to My Shelf

Publisher

Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio

Subject

2019-nCoV Vaccine mRNA-1273

/ Antiretroviral therapy